A carregar...
Publicação
Pre-operative exposure to tofacitinib is as safe as biologics in patients with ulcerative colitis undergoing colectomy: a multicentre observational study
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 608.52 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Patients with ulcerative colitis (UC) receiving immunomodulators are at substantial risk of colectomy. Since robust evidence regarding the post-operative outcomes of patients treated with anti-JAKs in the pre-operative phase is lacking, we aimed to assess the risk of complications of tofacitinib exposure prior to colectomy in comparison with anti-TNFs, vedolizumab, and ustekinumab.
Descrição
Palavras-chave
Contexto Educativo
Citação
Editora
Oxford University Press